Introduction: In Parkinson's Disease (PD), despite available treatments focusing on symptom alleviation, the effectiveness of conventional therapies decreases over time. This study aims to enhance the identification of candidates for device-aided therapies (DAT) using artificial intelligence (AI), addressing the need for improved treatment selection in advanced PD stages.
Methods: This national, multicenter, cross-sectional, observational study involved 1086 PD patients across Spain.
Background And Purpose: Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion is a recently developed device-aided therapy for advanced Parkinson disease (PD) patients. The aim of this study was to report real-world evidence about the effectiveness, tolerability, and safety of LECIG in PD patients.
Methods: A multicenter observational retrospective study of the first patients who initiated LECIG in Spain was performed.
Background: Levodopa-induced dyskinesias (LID) are frequent in Parkinson's disease (PD).
Objective: To analyze the change in the frequency of LID over time, identify LID related factors, and characterize how LID impact on patients' quality of life (QoL).
Patients And Methods: PD patients from the 5-year follow-up COPPADIS cohort were included.